Imatinib mesylate (STI-571 or Gleevec), is the first BCR-ABL tyrosine kinase inhibitor (TKI) to be used for the treatment of CML [2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.